Evidence map›Paper›PMID 40637995›Full record

ArticleScience China. Life sciences2025

Selective expansion of TCF7-expressing tumor-reactive T cell subpopulations during ovarian tumor-infiltrating T cell production ex vivo.

Dingfeng Liu, Ting Zhang, Qinli Sun, Dongli Cai, Yanan Lou, Genyu Wang, Bowen Xie, Yicheng Zhu, Chong Wang, Zhouping Lu and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Intratumoral PD-1Medical oncology (Northwood, London, England) · 2026
    Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Dingfeng LiuClinical and Translational Research Center, Department of Biobank, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China.
Ting ZhangShanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China.
Qinli SunInstitute for Immunology, Tsinghua University, Beijing, 100084, China.
Dongli CaiClinical and Translational Research Center, Department of Biobank, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China.
Yanan LouShanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China.
Genyu WangShanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China.
Bowen XieInstitute for Immunology, Tsinghua University, Beijing, 100084, China.
Yicheng ZhuShanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China.
Chong WangDepartment of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
Zhouping LuClinical and Translational Research Center, Department of Biobank, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China.
Chenfei LiuClinical and Translational Research Center, Department of Biobank, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China.
Yuan LiDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
Xi ZhangDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
Tianhui HeDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
Jing HaoShanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China.
Xinyi GuoShanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China.
Jiaming LiInstitute for Immunology, Tsinghua University, Beijing, 100084, China.
Xiaowei XiDepartment of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
Ling NiInstitute for Immunology, Tsinghua University, Beijing, 100084, China.
Hongyan GuoDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China. bysyghy@163.com.
Jing GeWestlake University School of Medicine, Hangzhou, 310024, China. gejing@westlake.edu.cn.
Liping JinClinical and Translational Research Center, Department of Biobank, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China. jinlp01@163.com.
Chen DongShanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China. dongchen@westlake.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-infiltrating lymphocyte (TIL) therapy was recently approved for melanoma patients; however, the dynamic changes in T cell subpopulations during TIL production remain poorly understood. Here, we analyzed epithelial ovarian cancer samples at various stages of ex vivo TIL culture using paired single-cell RNA and TCR sequencing. We also assessed the expansion potential and tumor reactivity of the identified TIL subpopulations. Single-cell transcriptomic analysis revealed that CD8

Indexed as

Carcinoma, Ovarian EpithelialHepatocyte Nuclear Factor 1-alphaLymphocytes, Tumor-InfiltratingOvarian NeoplasmsT Cell Transcription Factor 1T-Lymphocyte SubsetsAnimalsCD8-Positive T-LymphocytesFemaleHumansReceptors, Antigen, T-CellSingle-Cell AnalysisHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanReceptors, Antigen, T-CellT Cell Transcription Factor 1TCF7 protein, humanadoptive cell therapyexpansionovarian cancertumor-infiltrating lymphocytetumor reactivity

Identifiers

PMID40637995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.